^
BIOMARKER:

MET overexpression

i
Other names: DFNB97, AUTS9, RCCP2, C-Met, HGFR, HGF Receptor, Met Proto-Oncogene, HGF/SF Receptor, Proto-Oncogene C-Met, Scatter Factor Receptor, Tyrosine-Protein Kinase Met, Hepatocyte Growth Factor Receptor, MET, MET Proto-Oncogene, Receptor Tyrosine Kinase
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
MET overexpression
Non Small Cell Lung Cancer
REGN5093
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
MET overexpression
Non Small Cell Lung Cancer
SCC244
Sensitive
:
C2
MET overexpression
Lung Non-Squamous Non-Small Cell Cancer
ABBV-399
Sensitive
:
C2
MET overexpression
Non Small Cell Lung Cancer
erlotinib + ARQ 197
Sensitive
:
C3
MET overexpression
Gastric Cancer
ARQ 197
Sensitive
:
C3
MET overexpression
Melanoma
vemurafenib
Resistant
:
C3
MET overexpression
Colorectal Cancer
EGFR inhibitor
Resistant
:
C3
MET overexpression
Glioblastoma
bevacizumab
Resistant
:
C3
MET overexpression
Hepatocellular Cancer
tepotinib
Sensitive
:
C3
MET overexpression
Gastric Cancer
crizotinib
Sensitive
:
C3
MET overexpression
Gastric Cancer
savolitinib
Sensitive
:
C3
MET overexpression
Pancreatic Cancer
cetuximab
Resistant
:
C4
MET overexpression
Pancreatic Cancer
trametinib + dabrafenib
Resistant
:
C4
MET overexpression
Pancreatic Cancer
TR1801-ADC
Sensitive
:
D
MET overexpression
Adrenal Cortex Carcinoma
cabozantinib capsule
Sensitive
:
D
MET overexpression
Lung Adenocarcinoma
CKD-702
Sensitive
:
D
MET overexpression
Melanoma
BRAF inhibitor + MEK inhibitor
Resistant
:
D
MET overexpression
Hepatocellular Cancer
WXSH0011
Sensitive
:
D
MET overexpression
Gastric Cancer
tepotinib
Sensitive
:
D
MET overexpression
Non Small Cell Lung Cancer
crizotinib + chidamide
Sensitive
:
D
MET overexpression
Non Small Cell Lung Cancer
MG132
Sensitive
:
D
MET overexpression
Gastric Cancer
WXSH0011
Sensitive
:
D
MET overexpression
Gastric Cancer
Sym015
Sensitive
:
D